1. Scrip

Sun Governance Efforts, Ilumya US Run In Focus Ahead Of Q4

 
• By Anju Ghangurde

Ahead of its Q4 earnings, Sun Pharma has indicated its intent to take additional steps to address investor unease and perceptions around gaps in corporate governance. Investors are expected to keep a close watch on the company's efforts in these areas as well as on management commentary around the US uptake of psoriasis asset Ilumya.

SC1812_Goverance_228355783_1200.jpg
SUN TAKES MORE MEASURES TO ADDRESS GOVERNANCE CONCERNS • Source: Shutterstock

India’s top-ranked drug firm Sun Pharmaceutical Industries Ltd. continues to take steps to assuage investor concerns around alleged corporate governance lapses, with a forthcoming board meeting expected to formalize plans for a dedicated committee to oversee governance-related issues.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.